[go: up one dir, main page]

WO2009035855A3 - Novel uses of halogenated alkyl sulfonamides - Google Patents

Novel uses of halogenated alkyl sulfonamides Download PDF

Info

Publication number
WO2009035855A3
WO2009035855A3 PCT/US2008/074535 US2008074535W WO2009035855A3 WO 2009035855 A3 WO2009035855 A3 WO 2009035855A3 US 2008074535 W US2008074535 W US 2008074535W WO 2009035855 A3 WO2009035855 A3 WO 2009035855A3
Authority
WO
WIPO (PCT)
Prior art keywords
halogenated alkyl
novel uses
alkyl sulfonamides
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/074535
Other languages
French (fr)
Other versions
WO2009035855A2 (en
Inventor
Mary W Walker
Carlos Forray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of WO2009035855A2 publication Critical patent/WO2009035855A2/en
Publication of WO2009035855A3 publication Critical patent/WO2009035855A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of treating disorders relating to mood, anxiety, stress, sleep, cognitive impairment/dysfunction, substance dependency/abuse, metabolism, eating and chronic pain comprising administering a therapeutically effective amount of a compound of Formula I, and to uses of a compound of Formula 1 in the manufacture of a medicament for treating said disorders.
PCT/US2008/074535 2007-09-12 2008-08-28 Novel uses of halogenated alkyl sulfonamides Ceased WO2009035855A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97178707P 2007-09-12 2007-09-12
US60/971,787 2007-09-12

Publications (2)

Publication Number Publication Date
WO2009035855A2 WO2009035855A2 (en) 2009-03-19
WO2009035855A3 true WO2009035855A3 (en) 2009-04-30

Family

ID=40452775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/074535 Ceased WO2009035855A2 (en) 2007-09-12 2008-08-28 Novel uses of halogenated alkyl sulfonamides

Country Status (1)

Country Link
WO (1) WO2009035855A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280703A1 (en) * 2008-03-12 2011-02-09 Københavns Universitet (University Of Copenhagen) Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
CA2834429C (en) 2011-04-27 2019-07-02 Kyohei Hayashi 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035944A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
US6218408B1 (en) * 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US20060293341A1 (en) * 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035944A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
US6218408B1 (en) * 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US20060293341A1 (en) * 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives

Also Published As

Publication number Publication date
WO2009035855A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
IL197568A0 (en) Treating pain, diabetes, and disorders of lipid metabolism
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
IL202515A (en) Thyroid-like compounds and their use for the preparation of medicaments for treatment of metabolic disorders
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
PL2019683T5 (en) Administration of growth factors for the treatment of cns disorders
MY146388A (en) Thiazole pyrazolopyrimidines as crfi receptor antagonists
WO2008116129A3 (en) Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
CL2007003440A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9 DESATURASA; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISEASES SUCH AS TYPE 2 DIABETES, INSULIN RESISTANCE, LIPID DISORDERS, OBESIDA
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
SI2205244T1 (en) METHODS OF ADMINISTERING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-s4-S7-(2-MORPHOLIN-4-YL-ETHOXY-)IMIDAZO-S2,1-BC-S1,3C-BENZOTHIAZOL-2-YLC-PHENYLcUREA TO TREAT PROLIFERATIVE DISEASE
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
PL1919450T3 (en) Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2008055022A3 (en) Carbamate compounds for use in treating depression
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
WO2009035855A3 (en) Novel uses of halogenated alkyl sulfonamides
WO2007104933A8 (en) Chemical compounds
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007114916A3 (en) Arylbenzylpiperidine compounds
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830802

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830802

Country of ref document: EP

Kind code of ref document: A2